{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:24:24Z","timestamp":1764937464060,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T00:00:00Z","timestamp":1711238400000},"content-version":"am","delay-in-days":358,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.clgc.2022.09.009","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T20:49:49Z","timestamp":1664052589000},"page":"e35-e43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real World Data of Diagnosis, Survival, and Treatment Outcomes in Patients With Metastatic Non Clear Cell Renal Cell Carcinoma"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4116-8243","authenticated-orcid":false,"given":"Floriane","family":"Izarn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7275-0773","authenticated-orcid":false,"given":"Beno\u00eet","family":"Allignet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1465-2814","authenticated-orcid":false,"given":"Romane","family":"Gille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eve-Marie","family":"Neidhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"N\u00e9grier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude","family":"Fl\u00e9chon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2022.09.009_bib0001","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2022.09.009_bib0002","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","article-title":"Epidemiology of renal cell carcinoma [figure presented]","volume":"75","author":"Capitanio","year":"2019","journal-title":"Eur Urol [Internet]"},{"key":"10.1016\/j.clgc.2022.09.009_bib0003","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.juro.2009.12.035","article-title":"Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma","volume":"183","author":"Leibovich","year":"2010","journal-title":"J Urol [Internet]"},{"key":"10.1016\/j.clgc.2022.09.009_bib0004","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0022-5347(05)66077-6","article-title":"A postoperative prognostic nomogram for renal cell carcinoma","volume":"166","author":"Kattan","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2022.09.009_bib0005","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1002\/cncr.28151","article-title":"Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria","volume":"119","author":"Kroeger","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2022.09.009_bib0006","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.09.009_bib0007","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.09.009_bib0008","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.09.009_bib0009","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.annonc.2020.11.016","article-title":"Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 1","volume":"32","author":"Powles","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2022.09.009_bib0010","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1470-2045(15)00515-X","article-title":"Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): A multicentre, open-label, randomised phase 2 trial","volume":"17","author":"Armstrong","year":"2016","journal-title":"Lancet Oncol [Internet]"},{"key":"10.1016\/j.clgc.2022.09.009_bib0011","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.eururo.2015.10.049","article-title":"Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (espn): a randomized multicenter phase 2 trial","volume":"69","author":"Tannir","year":"2016","journal-title":"Eur Urol [Internet]"},{"key":"10.1016\/j.clgc.2022.09.009_bib0012","unstructured":"Evans AE, Angio GJD, Sather HN. Median Follow-Up in Clinical Trials. 2019;191\u20132."},{"key":"10.1016\/j.clgc.2022.09.009_bib0013","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs\u2014part a: renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol [Internet]"},{"key":"10.1016\/j.clgc.2022.09.009_bib0014","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2002.11.123","article-title":"Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.09.009_bib0015","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/annonc\/mdx075","article-title":"Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC","volume":"28","author":"Knox","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2022.09.009_bib0016","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2022.09.009_bib0017","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1200\/JCO.20.02365","article-title":"Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non\u2013clear cell renal cell carcinoma","volume":"39","author":"McDermott","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.09.009_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0319-9","article-title":"Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma","volume":"6","author":"Koshkin","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clgc.2022.09.009_bib0019","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1634\/theoncologist.2019-0372","article-title":"Nivolumab for the treatment of patients with metastatic non-clear cell renal cell carcinoma (nccRCC): a single-institutional experience and literature meta-analysis","volume":"25","author":"Chahoud","year":"2020","journal-title":"Oncologist"},{"issue":"suppl 6","key":"10.1016\/j.clgc.2022.09.009_bib0020","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1200\/JCO.2021.39.6_suppl.309","article-title":"Nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC): Safety and efficacy from CheckMate 920","volume":"39","author":"Tykodi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.09.009_bib0021","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejca.2022.05.002","article-title":"Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy","volume":"171","author":"Graham","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2022.09.009_bib0022","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.urolonc.2019.11.006","article-title":"Systemic therapy for chromophobe renal cell carcinoma: a systematic review","volume":"38","author":"Papanikolaou","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2022.09.009_bib0023","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.21.01944","article-title":"Phase II trial of cabozantinib plus nivolumab in patients with non\u2013clear-cell renal cell carcinoma and genomic correlates","volume":"40","author":"Lee","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.09.009_bib0024","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1093\/annonc\/mdr610","article-title":"Sarcoma: Concordance between initial diagnosis and centralized expert review in a population-based study within three European regions","volume":"23","author":"Ray-coquard","year":"2012","journal-title":"Ann Oncol [Internet]"},{"key":"10.1016\/j.clgc.2022.09.009_bib0025","doi-asserted-by":"crossref","unstructured":"Trpkov K, Hes O, Williamson SR, et\u00a0al. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia [Internet]. Vol. 34, Modern Pathology. Springer US; 2021. 1392\u20131424 p. Available from: 10.1038\/s41379-021-00779-w","DOI":"10.1038\/s41379-021-00779-w"},{"key":"10.1016\/j.clgc.2022.09.009_bib0026","doi-asserted-by":"crossref","unstructured":"Carlo MI, Khan N, Zehir A, Patil S, Ged Y, Redzematovic A. Original report abstract comprehensive genomic analysis of metastatic non \u2013 clear-cell renal cell carcinoma to identify therapeutic targets. 2020;1\u201318.","DOI":"10.1200\/PO.18.00372"},{"key":"10.1016\/j.clgc.2022.09.009_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102191","article-title":"Non-clear cell renal carcinomas: review of new molecular insights and recent clinical data","volume":"97","author":"Barth\u00e9l\u00e9my","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2022.09.009_bib0028","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(21)00152-5","article-title":"A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial","volume":"397","author":"Pal","year":"2021","journal-title":"Lancet [Internet]"},{"key":"10.1016\/j.clgc.2022.09.009_bib0029","first-page":"1","article-title":"Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets","volume":"7","author":"Chen","year":"2016","journal-title":"Nat Commun [Internet]"},{"key":"10.1016\/j.clgc.2022.09.009_bib0030","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.eururo.2015.06.019","article-title":"Characterization of clinical cases of collecting duct carcinoma of the kidney assessed by comprehensive genomic profiling","volume":"70","author":"Pal","year":"2016","journal-title":"Eur Urol [Internet]"},{"issue":"suppl 15","key":"10.1016\/j.clgc.2022.09.009_bib0031","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1200\/JCO.2020.38.15_suppl.5004","article-title":"Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer","volume":"38","author":"Srinivasan","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.09.009_bib0032","article-title":"Kidney cancer: from genes to therapy","volume":"45","author":"Webster","year":"2021","journal-title":"Curr Probl Cancer [Internet]"},{"key":"10.1016\/j.clgc.2022.09.009_bib0033","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.09.009_bib0034","doi-asserted-by":"crossref","first-page":"488","DOI":"10.4143\/crt.2016.584","article-title":"Pazopanib for the treatment of non-clear cell renal cell carcinoma: a single-arm, open-label, multicenter, phase II study","volume":"50","author":"Jung","year":"2018","journal-title":"Cancer Res Treat"},{"issue":"suppl 15","key":"10.1016\/j.clgc.2022.09.009_bib0035","doi-asserted-by":"crossref","first-page":"TPS4595","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS4595","article-title":"KEYNOTE-B61: open-label phase 2 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)","volume":"39","author":"Lee","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.09.009_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamanetworkopen.2020.21869","article-title":"Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival","volume":"4","author":"Dudani","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2022.09.009_bib0037","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2020.02.001","article-title":"Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: results of the multicentre, open-label, single-arm, phase II AXIPAP trial","volume":"129","author":"Negrier","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2022.09.009_bib0038","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/annonc\/mdv149","article-title":"First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: A phase II study (SUPAP) by the French Genitourinary Group (GETUG)","volume":"26","author":"Ravaud","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2022.09.009_bib0039","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejca.2016.08.004","article-title":"Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis","volume":"69","author":"Escudier","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2022.09.009_bib0040","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jamaoncol.2020.2218","article-title":"Efficacy of savolitinib vs sunitinib in patients with MET -driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial","volume":"6","author":"Choueiri","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2022.09.009_bib0041","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.19.01882","article-title":"Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and\/or sarcomatoid features","volume":"38","author":"McGregor","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322002051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322002051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:36:26Z","timestamp":1761564986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767322002051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1558767322002051"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2022.09.009","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real World Data of Diagnosis, Survival, and Treatment Outcomes in Patients With Metastatic Non Clear Cell Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2022.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}